Piramal Pharma Ltd. · PPLPHARMA
Every Piramal Pharma Ltd. result whose ten-session window has closed, judged against the last read made before it. Sector index NIFTY PHARMA. Open a result for the full account: the read, the sessions after, the reported figures, and every morning's read that led up to it. The company's own page →
16results judged
1read right
2read wrong
3flat / no call
10unread
44%beat the market
+2.1%avg vs market, 10d
4.2%avg move, T+1
How the reads on it fared
| Read | Judged | Right | Wrong | Flat | Hit rate | Avg vs mkt | |
|---|---|---|---|---|---|---|---|
| strong | 1 | 1 | 0 | 0 | 100% | +8.1% | |
| favourable | 1 | 0 | 1 | 0 | 0% | -7.7% | |
| neutral | 3 | 0 | 0 | 3 | — | -2.1% | |
| unfavourable | 1 | 0 | 1 | 0 | 0% | +4.2% | |
| unread | 10 | 0 | 0 | 0 | — | +3.5% |
A company that is often read strong and often proves it is one the model understands; one that is read strong and keeps lagging is where the model is wrong about a name, and this table is where that shows first.
Reading the rows
- T+1
- the share's move on the first session after the result, from the close before it
- T+10
- the move over ten sessions, same base
- vs market
- T+10 less NIFTY 50's move over the same ten sessions — the number every read is judged on
- Run-up
- the share's move in the thirty sessions before the result
- Result
- reported profit growth against the company's own last four quarters: good, in line, bad
Each result
16 judged · newest first · open one| Result | Read | Outcome | T+1 | T+10 | vs market | Run-up | Result | Why | |
|---|---|---|---|---|---|---|---|---|---|
| 29 Jul Q1FY27 | strong | right | -0.0% | +8.7% | +8.1% | +20% | no figures |
|
› |
| 28 Apr Q4FY26 | neutral | neutral | -1.6% | +6.1% | +7.4% | +18% | no figures |
|
› |
| 28 Jan Q3FY26 | unfavourable | wrong | +0.5% | +6.1% | +4.2% | -10% | no figures |
|
› |
| 5 Nov Q2FY26 | favourable | wrong | -0.6% | -5.4% | -7.7% | -4% | no figures |
|
› |
| 28 Jul Q1FY26 | neutral | neutral | -1.5% | -7.3% | -6.5% | +3% | no figures |
|
› |
| 14 May Q4FY25 | neutral | neutral | -6.5% | -6.4% | -7.0% | +0% | no figures |
|
› |
| 28 Jan Q3FY25 | — | unread | +5.8% | -8.4% | -8.8% | -13% | no figures |
|
› |
| 23 Oct Q2FY25 | — | unread | +12.1% | +34.1% | +35.0% | -6% | no figures |
|
› |
| 26 Jul Q1FY25 | — | unread | +2.4% | +9.2% | +9.3% | +8% | no figures |
|
› |
| 10 May Q4FY24 | — | unread | -1.0% | -0.3% | -4.1% | +24% | no figures |
|
› |
| 30 Jan Q3FY24 | — | unread | -0.5% | -2.1% | -3.6% | +10% | no figures |
|
› |
| 28 Oct Q2FY24 | — | unread | +13.0% | +27.7% | +25.7% | -8% | no figures |
|
› |
| 3 Aug Q1FY24 | — | unread | -3.9% | -5.5% | -5.6% | +12% | no figures |
|
› |
| 25 May Q4FY23 | — | unread | +4.6% | +12.1% | +10.4% | +13% | no figures |
|
› |
| 9 Feb Q3FY23 | — | unread | -10.9% | -16.3% | -14.3% | -15% | no figures |
|
› |
| 10 Nov Q2FY23 | — | unread | -2.4% | -6.5% | -9.2% | — | no figures |
|
› |